Ratings Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Real-time Estimate Cboe BZX Other stock markets 02:26:46 2024-06-06 pm EDT			5-day change	1st Jan Change
1,000 ^USD	-0.56%		+3.05%	+13.79%

Jun. 05	Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing	MT
Jun. 05	Transcript : Regeneron Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 08:30 AM

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is good.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

With an expected P/E ratio at 29.73 and 26.58 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
REGENERON PHARMACEUTICALS, INC.	+13.79%	109B	B+
VERTEX PHARMACEUTICALS INCORPORATED	+18.20%	125B	B+
BIONTECH SE	-3.41%	24.74B	B+
ARGENX SE	+2.71%	22.67B	B
GENMAB A/S	-9.95%	18.14B	A-
WUXI APPTEC CO., LTD.	-41.48%	16.67B	A-
BEIGENE, LTD.	-11.88%	16.64B	B
NEUROCRINE BIOSCIENCES, INC.	-0.10%	13.45B	C+
SAREPTA THERAPEUTICS, INC.	+21.97%	11.32B	C+
INSMED INCORPORATED	+87.74%	9.32B	C

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes